Yes. Japan’s conditional and time-limited approval for regenerative medical products can expire. PMDA explicitly lists Collategene’s marketing authorization as expired 0004. But reaching the original end date does not always mean approval has lapsed: the law allows a formal extension in specified circumstances, and a timely re-application can keep the existing approval effective while a decision is pending T_doc?dataId=81004000&dataType=0. Check the current regulatory status, not just the date on an old approval announcement.
This article covers Japan’s regenerative medical product pathway, not every country’s conditional approval system. Information checked November 4, 2026; this is general regulatory information, not personal medical or legal advice.

When conditional approval can expire
Conditional approval is permission to market a named product under conditions for a limited period. It is not permanent approval or proof that the treatment will benefit every eligible patient. Japan’s pathway allows earlier access when efficacy can reasonably be predicted and safety has been assessed, with further evaluation after marketing 20260220.
Article 23-26 of the PMD Act sets an initial term of no more than seven years. Paragraph 2 allows MHLW to extend that term by up to three years when it considers this particularly necessary for the statutory review, after consulting the Pharmaceutical Affairs Council. An extension is a regulatory decision, not something a company or clinic can assume T_doc?dataId=81004000&dataType=0.
The holder must re-apply within the applicable term, including any formally extended term. Crucially, paragraph 6 says that when this application has been made and remains undecided at the deadline, the existing conditional approval stays effective until the decision. Submitting the application in time is not the same as having to obtain full approval before the deadline. Neither is continued validity during review a grant of full approval T_doc?dataId=81004000&dataType=0.
Expiry is different from rejection
- Expiry: the authorization has lapsed. PMDA uses the wording “Marketing authorization has expired” for Collategene 0004.
- Rejection: regulators refuse the application for full approval. PMDA records “Full approval was rejected (as of July 24, 2024)” for HeartSheet. This is a distinct regulatory outcome, not another name for expiry 0004.
- Standard approval: re-application leads to a further regulatory decision; a favorable outcome is not guaranteed by the original conditional approval 20260220.
An expired authorization cannot be presented as current permission to market that product. However, an old approval date alone cannot establish whether a product has expired, received an extension, or remains authorized during review. Look for the applicable decision and status record T_doc?dataId=81004000&dataType=0.
What the product records show
The following examples illustrate different outcomes and terms; they are not a complete inventory or a calculation of the pathway’s success rate.
| Product | Documented approval history | What to take from it |
|---|---|---|
| Collategene (beperminogene perplasmid) | Conditional and time-limited approval in March 2019; PMDA records that marketing authorization has expired 0004. | A real example of expiry, not merely a theoretical deadline. |
| HeartSheet (autologous skeletal myoblast-derived cell sheet) | Conditional and time-limited approval in September 2015; PMDA records rejection of full approval as of July 24, 2024 0004. | Initial conditional approval does not guarantee later full approval. |
| AMCHEPRY (raguneprocel, iPS cell-derived) | Approval with conditions and time limits on March 6, 2026. The review report specifies a seven-year duration and an indication for improvement of Parkinson’s disease motor symptoms in patients with inadequate response to existing medication 20260220 000281617.pdf. | The seven-year term belongs to this product; it is not a universal duration. |
| RiHEART (allogeneic iPS cell-derived cardiomyocyte sheet) | Approval with conditions and time limits on March 6, 2026. The review report specifies a seven-year duration and treatment of severe heart failure associated with ischemic cardiomyopathy 20260220 000281693.pdf. | Check the named product and approved indication, not a general claim about iPS cells. |
For AMCHEPRY and RiHEART, the review reports require post-marketing surveillance covering all treated patients until the standard-approval application is submitted. Those requirements explain why approval is conditional; they are not evidence that follow-up has already confirmed benefit 000281617.pdf 000281693.pdf.
A practical way to read an approval
Take AMCHEPRY as a document-reading example. Its review report has a “Duration of Approval” entry stating “7 years.” That answers how long the approval was initially granted for. It does not, by itself, answer whether a later extension or decision exists. Collategene illustrates the complementary check: PMDA’s index carries an explicit expiry note 000281617.pdf 0004.
Read the original duration and the later status together. A review report explains the approval’s terms; a subsequent regulatory record may change what those terms mean today.
This is a worked example using public regulatory documents, not a patient story or a claim of clinical experience. It cannot establish whether an individual patient is eligible or whether a hospital currently has access to the product.
What expiry does not tell you
Expiry alone does not prove that every previously treated patient received poor care or that a product was unsafe. Nor does it explain why authorization ended. Separate the recorded regulatory outcome from conclusions about efficacy, safety, or an individual patient’s treatment.
A clinic procedure follows a separate safety-law framework. The Act on the Safety of Regenerative Medicine requires advance submission of a provision plan for procedures within its scope. Filing that plan is not product marketing approval and does not itself demonstrate efficacy En.
A trial registration, published paper, or similar cell type also cannot substitute for approval of the exact product, indication, and route being offered. Laboratory and animal findings alone do not establish benefit in people.
What to check before treatment
Before paying or booking medical travel, ask the provider for:
- The product’s brand and generic names, approved indication, eligible population, and administration method.
- The approval decision, initial duration, and any formal extension or later decision.
- If the original deadline has passed, the documentary basis for continued authorization, including any timely re-application still under review.
- A written plan for follow-up, treatment alternatives, and any remaining payments if authorization changes during care.
Use PMDA’s product entry and linked review documents to cross-check the names and approval history 0004. If the records do not resolve a post-deadline status question, ask for the relevant MHLW decision rather than calculating validity from the original date alone.
Ask the treating hospital separately whether it can offer that product for your diagnosis and how it will manage continuing care. Do not assume that loss of marketing authorization ends medical follow-up, or make treatment changes without discussing them with your clinician. Approval does not guarantee access or benefit.
If the offer is a filed-plan procedure instead of an approved product, request the plan number, reviewing committee, and current procedure details. Ask for human evidence matching your condition, cell type, and administration route, including study design, patient numbers, follow-up, and reported adverse events.
The bottom line
Yes, conditional approval can expire; Collategene is a documented Japanese example. But an original deadline is not enough to establish expiry. Check formal extensions, any continued validity during review, and the latest product-specific regulatory decision before relying on an approval claim 0004 T_doc?dataId=81004000&dataType=0.
Have a question about the documents to request?
Contact us about preparing questions for your provider. Confirm product authorization with the relevant regulatory records and treatment decisions with your clinician.




